

P&T Committee Meeting Minutes

Subject:	Louisiana Department of Health Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street Baton Rouge, LA Bienville Building Room 118
Date:	April 26, 2019
Members Present:	<ul style="list-style-type: none">▪ Dr. Marcus Bachhuber▪ Dr. Jill Comeau▪ Dr. Donald (Chancellor)▪ Dr. James Hussey▪ Dr. Edward Mader▪ Dr. David Mushatt▪ Ben Orlando, RPh▪ Representative Roger Pope▪ Marty R. McKay, RPh▪ Senator Fred Mills, RPh▪ Dr. Cefalu
LDH Staff Present:	<ul style="list-style-type: none">▪ Melwyn Wendt, PharmD▪ Germaine Becks-Moody, PhD, BHSF▪ Sue Fontenot, RPh▪ Paul Knecht, MS, PharmD▪ April Holley PharmD, MBA▪ Ms. Haley Williams▪ Ms. Kim Sullivan
Contractors Present:	<ul style="list-style-type: none">▪ Hind Douiki, PharmD, Magellan Medicaid Administration▪ Kristina Carter, Certified Court Reporter

Others Present: Presenters are listed in the minutes and sign in sheets and others in attendance from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Marty R. McKay, Chairman, called the meeting to order at or around 9:03 a.m. after a quorum was reached with 9 members. He stated that this meeting will be conducted in compliance with the Open Meetings Law.

Parliamentary Business

- A. **Introduction of Members/Roll Call.** Committee members introduced themselves. LDH and Magellan staff also introduced themselves.
- B. **Additional agenda items.** The Chair entertained requests for additional agenda items. Hearing none, Mr. McKay stated that the posted agenda will be adopted. He also asked for a motion from the members to have the ability to reorder the agenda as deemed appropriate. Representative Pope made a motion to accept; Dr. Donald seconded it.
- C. **Approval of Minutes.** Mr. McKay asked for a motion to approve the minutes from November 2, 2018. There were no objections to approving the minutes.
- D. **Single-PDL Update.** Dr. Steele thanked everyone who has been involved in the Single PDL initiative, which will be implemented on May 1, 2019. She expressed enormous gratitude to the Pharmacy Staff and Dr. Marcus who worked hard to ensure the brand medications that are preferred over generics had minimal financial impact on pharmacies. She indicated that a Pharmacy Advisory Council has been formed specifically for this purpose. Dr. Steele also thanked the committee members for attending the meeting.

P&T Committee Overview (Kim Sullivan)

A. P & T Background

Ms. Sullivan provided background that the committee was established by state statute. Last year, there was a legislation that reduced the committee number to 15 in order to establish quorum more easily. The purpose of the committee is to make recommendations for additions and deletions to the Preferred Drug List. The committee is also responsible for advising the Secretary on any policy recommendations related to the Medicaid Pharmacy Program.

B. P & T Bylaws

Ms. Sullivan informed the committee that LDH has to amend the bylaws to reflect the new composition. For the next meeting, committee members will receive in their packets changes to the bylaws. This would allow them to vote at the next meeting on those changes because the bylaws must be updated to reflect the changes in the statute.

Ethics Review (Haley Williams)

Ms. Williams reminded all that P&T Committee members are subject to the Governmental Code of Ethics and are required to complete the Annual Ethics Training online. She stated that the Code of Governmental Ethics sets forth objective standards of conduct to protect the integrity of government programs, that decisions and policies are made in the proper channel, and that public positions are not used for private gain.

Ms. Williams also provided an overview of Section 1111 of the Ethics Code, which prohibits members from receiving compensation (money or anything of economic value) from a source other than LDH for the performance of any service that is too closely related to the duties, responsibilities, or operations of this committee, draws upon official data or ideas of this committee that are not yet part of the public record, or if the person making the payment is a prohibited source. Additionally, Section 1117 of the Ethics Code prohibits a person from giving a member anything that the member is prohibited from receiving.

Mr. McKay asked Dr. Wendt to email the ethics training link to each committee member.

Reports

Dr. Wendt provided the committee with information regarding the documents included in each member's packet.

- A. The Preferred Drug List program overview and results for fiscal year 2018.
- B. A copy of the current PDL that is in place for Fee-For-Service that took effect in January 2019 and will be in place through the end of June. Dr. Holley provided an overview of the legends that are on the PDL.

Senator Mills asked Dr. Wendt if being a part of the TOP\$ pool remains the best option for the state and Dr. Wendt reassured him that it continues to be the case. Dr. Wendt also informed Senator Mills there is an open RFP which has not been awarded yet, and that it includes enhancements to the PDL.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Dr. Douiki provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates. They should also have cost sheets which include relative values, rather than actual numbers, in order to comply with the privacy laws regarding rebates.

B. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Kurt Talamo	Novartis	Entresto
Sarah Mahne	Insmad	Arikayce
Maggie Murphy	Teva	Ajovy
Avatar Jones	Artia Solutions	Hemangeol
Doug Welch	Merck	Steglatro
Bobby Greenly	Biogen	Tecfidera
DR. CEFALU	(Not Stated)	Opiate Dependence Treatments
Shelley Thompson	Alkermes	Vivitrol
Valerie Ng	Indivior	Sublocade
Laura Gautreaux	US WorldMeds	Lucemyra
Susan Steinbis	United Therapeutics	Orenitram
Bruce Neale	Actelion	Opsumit and Uptravi
Steve St. Onge	Paratek	Nuzyra
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

Acne Agents, Topical – New

Mr. Orlando made the motion to amend the recommendation. Dr. Bachhuber seconded the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Clindamycin Phosphate Gel
- Clindamycin Phosphate Med. Swab
- Clindamycin Phosphate Solution
- Erythromycin Gel
- Erythromycin Solution

Analgesics Narcotics, Long

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. Dr. Donald made the motion to keep fentanyl patch as preferred on the PDL. After discussion and unanimous vote, there was no objection to the motion.

Committee recommendations for the PDL are:

- Fentanyl transderm
- Morphine ER tablet
- Embeda

Analgesics Narcotics, Short

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Apap/Codeine elixir, tablet
- Hydrocodone/apap solution/tablet
- Hydromorphone tablet
- Morphine Syringe
- Morphine IR tablet
- Oxycodone/apap tablet
- Oxycodone tablet
- Tramadol
- Tramadol/apap

Androgenic Agents

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Androderm
- Testosterone Gel (Generic Vogelxo)
- Testosterone Gel Packet (Generic Vogelxo)

- Testosterone Gel Pump (Generic Vogelxo)

Angiotensin Modulator Combinations

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Amlodipine/benazepril
- Amlodipine/valsartan
- Amlodipine/valsartan/HCTZ

Angiotensin Modulators

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Benazepril
- Enalapril
- Enalapril/HCTZ
- Entresto
- Fosinopril/HCTZ
- Irbesartan
- Irbesartan/HCTZ
- Lisinopril
- Lisinopril/HCTZ
- Losartan
- Losartan/HCTZ
- Olmesartan

- Quinapril
- Ramipril
- Valsartan
- Valsartan/HCTZ

Antibiotics, GI

Dr. Mushatt made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Firvanq
- Metronidazole tablet
- Neomycin
- Vancomycin capsule

Antibiotics, Inhaled

Mr. Orlando made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Bethkis
- Tobramycin Pak

Antibiotics, Topical

Dr. Donald made the motion to accept. Dr. Mader seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Mupirocin ointment

Antibiotics, Vaginal

Mr. Orlando made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clindamycin
- Clindesse
- Metronidazole
- Nuvessa

Anticoagulants

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Eliquis
- Eliquis Dose pack
- Enoxaparin Syringe
- Enoxaparin Vial
- Pradaxa
- Warfarin
- Xarelto
- Xarelto dose pack

Antivertigo/Antiemetic Agents

Dr. Donald made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Meclizine
- Metoclopramide solution, tablet, vial
- Ondansetron ODT, solution, tablets, vial
- Prochlorperazine oral
- Promethazine ampule, rectal, syrup, tablet, vial
- Scopolamine

Antifungals, Oral

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clotrimazole mucous membrane
- Fluconazole suspension, tablet
- Griseofulvin suspension
- Nystatin suspension, tablet
- Terbinafine

Antifungals, Topical

Representative Pope made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clotrimazole cream Rx, solution Rx
- Clotrimazole-Betamethasone cream
- Ketoconazole cream, shampoo
- Nystatin cream, ointment, powder
- Nystatin-Triamcinolone cream

Antimigraine Agents, Other - New

Dr. Mader made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Emgality pen, syringe

Antimigraine Agents, Triptans

Dr. Donald made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Rizatriptan ODT, tablet
- Sumatriptan nasal, tablet, vial

Antiparasitics, Topical

Mr. Orlando made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Natroba
- Permethrin cream
- Sklice

Antivirals, Oral

Dr. Mader made the motion to accept. Dr. Bachhuber seconded the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Acyclovir capsule, suspension, tablet
- Famciclovir
- Oseltamivir suspension
- Tamiflu capsule
- Valacyclovir

Antivirals, Topical

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Acyclovir ointment

Beta Blockers

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Acebutolol
- Betaxolol
- Atenolol

- Atenolol/chlorthalidone
- Bisoprolol
- Bisoprolol/HCTZ
- Carvedilol
- Labetalol
- Metoprolol
- Metroprolol XL
- Propranolol ER
- Propranolol solution, tablet
- Sotalol

Bladder Relaxant Preparations

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Oxybutynin ER
- Oxybutynin syrup, tablet
- Toviaz
- Vesicare

Bone Resorption Suppression and Related Agents

Dr. Donald made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Alendronate tablet
- Calcitonin nasal

BPH Treatments

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Alfuzosin
- Doxazosin
- Dutasteride
- Finasteride
- Tamsulosin
- Terazosin

Calcium Channel Blockers

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Amlodipine
- Diltiazem capsule ER
- Diltiazem tablet
- Felodipine ER
- Nifedipine ER
- Verapamil ER PM
- Verapamil tablet
- Verapamil tablet ER

Cephalosporins and Related Antibiotics

Dr. Mushatt made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Amoxicillin/clavulanate suspension, tablet
- Cefadroxil capsule
- Cefdinir capsule, suspension
- Cefprozil suspension, tablet
- Cefuroxime tablet
- Cephalexin capsule, suspension

Cystic Fibrosis – New

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

- All of the drugs in this class are recommended nonpreferred

Fluoroquinolones

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Ciprofloxacin tablet
- Levofloxacin tablet

GI Motility, Chronic

Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Amitiza
- Linzess
- Movantik

Growth Hormone

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Genotropin cartridge
- Genotropin syringe
- Norditropin pen

H. Pylori Treatment

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

- All of the drugs in this class are recommended nonpreferred

Hypoglycemics, Alpha-Glucosidase Inhibitors

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Acarbose

Hypoglycemics, Incretin Mimetics/Enhancers

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Bydureon pen, vial
- Byetta pen
- Glyxambi

- Janumet
- Janumet XR
- Januvia
- Jentadueto
- Tradjenta
- Victoza

Hypoglycemics, Insulin and Related Agents

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Humalog Mix pen, vial
- Humalog pen, vial
- Humulin 500 u/mL vial
- Humulin 70/30 vial OTC
- Humulin vial OTC
- Lantus Solostar pen, vial
- Levemir pens, vial
- Novolog Mix pen, vial
- Novolog cartridge, pen, vial

Hypoglycemics, Meglitinides

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Nateglinide
- Repaglinide

Hypoglycemics, Metformins – New

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Glipizide-metformin
- Glyburide-metformin
- Metformin
- Metformin ER (generic Glucophage XR)

Hypoglycemics, SGLT2

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Invokana
- Jardiance

Hypoglycemics, Sulfonylureas

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Glimepiride
- Glipizide
- Glipizide ER
- Glyburide
- Glyburide micronized

Hypoglycemics, TZD

Dr. Donald made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Pioglitazone

Immunosuppressives, Oral

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Azathioprine
- Cyclosporine modified capsule
- Mycophenolate mofetil capsule, tablet
- Tacrolimus

Lincosamides/Oxazolidinones/Streptogramins

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Clindamycin capsule
- Clindamycin palmitate solution
- Linezolid tablet

Lipotropics, Other

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Cholestyramine/sucrose
- Colestipol granule, tablet
- EZETIMIBE
- Fenofibrate tablet (generic Tricor)
- Gemfibrozil
- Niacin ER

Lipotropics, Statins

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Atorvastatin
- Lovastatin
- Pravastatin
- Rosuvastatin

- Simvastatin

Macrolides/Ketolides

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Azithromycin packet, suspension, tablet
- Clarithromycin tablet
- Erythromycin Base capsule DR

Multiple Sclerosis Agents

Dr. Mader made the motion to accept. Dr. Donald seconded the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Avonex pen, vial
- Betaseron Kit
- Copaxone 20 mg/mL
- Gilenya
- Rebif injection, Rebidose

Nitrofurantoin Derivatives

Dr. Mushatt made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Nitrofurantoin macrocrystals capsule
- Nitrofurantoin mono-macro capsule

Opiate Dependence Treatments

Dr. Donald made the motion to accept. Dr. Bachhuber seconded the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Naloxone syringe, vial
- Naltrexone
- Narcan spray
- Suboxone film

PAH Agents, Oral and Inhaled

Dr. Donald made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Letairis
- Sildenafil
- Tracleer

Pancreatic Enzymes

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Creon
- Zenpep

Pediatric Vitamin Preparations – New

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Fluoride/Vitamins A, C, and D drops
- Multivitamins with Fluoride drops
- Multivits with Iron & Fluoride drops
- Pedi MVI No.16 with Fluoride chewable tablet
- Pedi MVI No.17 with Fluoride chewable tablet

Phosphate Binders

Dr. Bachhuber made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Calcium acetate capsule
- Renagel

Pituitary Suppressive Agents, LHRH

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Leuprolide Acetate
- Lupaneta Pack (injection/oral)
- Lupron Depot, Depot kit
- Lupron Depot-Ped kit
- Synarel
- Zoladex

Platelet Aggregation Inhibitors

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Brilinta
- Clopidogrel
- Dipyridamole
- Prasugrel

Proton Pump Inhibitors

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Lansoprazole
- Omeprazole
- Pantoprazole
- Protonix suspension

Sinus Node Inhibitors - New

Senator Mills made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

- Corlanor is currently the only agent in this class; the committee recommended it nonpreferred

Skeletal Muscle Relaxants

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Baclofen
- Chlorzoxazone
- Cyclobenzaprine
- Methocarbamol
- Tizanidine tablet

Tetracyclines

Dr. Mushatt made the motion to accept. Dr. Donald seconded the motion. Mr. Orlando had an objection to make tetracycline non-preferred; Dr. Comeau seconded it.

Committee recommendations for the PDL are:

- Doxycycline hyclate capsule, tablet
- Doxycycline monohydrate 50 mg and 100 mg capsule
- Doxycycline monohydrate tablet
- Minocycline capsule

Ulcerative Colitis Agents

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Apriso
- Balsalazide
- Mesalamine
- Sulfasalazine
- Sulfasalazine DR

Uterine Disorder Treatments – New

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Orilissa

Vasodilators, Coronary

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Isosorbide dinitrate
- Isosorbide mononitrate
- Isosorbide mononitrate SR
- Nitro-Bid ointment
- Nitroglycerin sublingual, transdermal

Single Drug Reviews

In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.

Presenter	Representing	Drug/Issue
Jason Swartz	Otsuka	Abilify MyCite
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

The single drugs were reviewed and a recommendation was made. P&T Committee recommendations follow:

Antipsychotics

Dr. Hussey made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Abilify MyCite

Colony Stimulating Factors

Dr. Donald made the motion to accept the recommendations. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Prefer Udenyca

COPD

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Yupelri

Neuropathic Pain

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Ztlido

Ophthalmics, Anti-Inflammatory

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Invelty

Ophthalmics, Anti-Inflammatory/Immunomodulator

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Cequa

Ophthalmics, Glaucoma Agents

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Xelpros

Steroids, Topical Very High

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Bryhali
- Non-prefer Lexette

Hepatitis C Model (Dr. Marcus Bachhuber)

With the goal of eliminating hepatitis C in Louisiana, LDH engaged with manufacturers in a competitive solicitation for offers with the goal of providing unlimited access to Medicaid members for no more than a fixed price to the Medicaid Program. The chosen manufacturer was Asegua for the authorized generic of Eplusa. If/when the agreement is executed, Dr. Bachhuber asked the committee to make the authorized generic of Eplusa as the preferred agent; and, if for any reason the agreement is not executed, the Department asks the committee to leave the current recommendation as is.

Dr. Bachhuber made the motion to accept. Mr. Orlando seconded the motion. After discussion, there was no objection to the motion.

Other Business

Dr. Wendt thanked the committee members for attending the meeting. She also requested to let the Department know of any problems encountered starting May 1st, 2019.

Proposed Therapeutic Classes to be Reviewed at Next Meeting


The committee members were shown the list of therapeutic classes that will be reviewed on the November 2019 meeting.

Next Meeting Date

The next P&T committee meeting is tentatively scheduled for November 6, 2019.

Adjournment

The meeting adjourned at or about 11:42 a.m.



11-4-22

Ben Orlando
Chairman/Co-Chairman P&T Committee

Date